314 related articles for article (PubMed ID: 27455511)
1. A rapid pro-hemostatic approach to overcome direct oral anticoagulants.
Thalji NK; Ivanciu L; Davidson R; Gimotty PA; Krishnaswamy S; Camire RM
Nat Med; 2016 Aug; 22(8):924-32. PubMed ID: 27455511
[TBL] [Abstract][Full Text] [Related]
2. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.
Lu G; DeGuzman FR; Hollenbach SJ; Karbarz MJ; Abe K; Lee G; Luan P; Hutchaleelaha A; Inagaki M; Conley PB; Phillips DR; Sinha U
Nat Med; 2013 Apr; 19(4):446-51. PubMed ID: 23455714
[TBL] [Abstract][Full Text] [Related]
3. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.
Lu G; Pine P; Leeds JM; DeGuzman F; Pratikhya P; Lin J; Malinowski J; Hollenbach SJ; Curnutte JT; Conley PB
PLoS One; 2018; 13(3):e0195122. PubMed ID: 29590221
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.
Carter RLR; Talbot K; Hur WS; Meixner SC; Van Der Gugten JG; Holmes DT; Côté HCF; Kastrup CJ; Smith TW; Lee AYY; Pryzdial ELG
J Thromb Haemost; 2018 Nov; 16(11):2276-2288. PubMed ID: 30176116
[TBL] [Abstract][Full Text] [Related]
5. Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors.
Kalathottukaren MT; Creagh AL; Abbina S; Lu G; Karbarz MJ; Pandey A; Conley PB; Kizhakkedathu JN; Haynes C
Blood Adv; 2018 Aug; 2(16):2104-2114. PubMed ID: 30135185
[TBL] [Abstract][Full Text] [Related]
6. Preclinical safety and efficacy of andexanet alfa in animal models.
Lu G; Hollenbach SJ; Baker DC; Tan S; Hutchaleelaha A; Curnutte JT; Conley PB
J Thromb Haemost; 2017 Sep; 15(9):1747-1756. PubMed ID: 28682477
[TBL] [Abstract][Full Text] [Related]
7. Strategies of neutralization of the direct oral anticoagulants effect: review of the literature.
Jourdi G; Le Bonniec B; Gouin-Thibault I
Ann Biol Clin (Paris); 2019 Feb; 77(1):67-78. PubMed ID: 30591426
[TBL] [Abstract][Full Text] [Related]
8. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.
Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C
Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXa
Parsons-Rich D; Hua F; Li G; Kantaridis C; Pittman DD; Arkin S
J Thromb Haemost; 2017 May; 15(5):931-937. PubMed ID: 28294526
[TBL] [Abstract][Full Text] [Related]
10. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
[TBL] [Abstract][Full Text] [Related]
11. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia.
Ivanciu L; Toso R; Margaritis P; Pavani G; Kim H; Schlachterman A; Liu JH; Clerin V; Pittman DD; Rose-Miranda R; Shields KM; Erbe DV; Tobin JF; Arruda VR; Camire RM
Nat Biotechnol; 2011 Oct; 29(11):1028-33. PubMed ID: 22020385
[TBL] [Abstract][Full Text] [Related]
12. Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L).
George LA; Thalji NK; Raffini LJ; Gimotty PA; Camire RM
J Thromb Haemost; 2015 Sep; 13(9):1694-8. PubMed ID: 26190406
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Pharmacokinetics, Pharmacodynamics, Tissue Distribution, and Interspecies Scaling of Recombinant Human Coagulation Factor Xa
Parng C; Markiewicz V; Chen J; Leary B; Duriga N; Dyleski L; Caiazzo T; Bolt M; Joyce A; Gorovits B; Pittman DD; Webster R
J Pharm Sci; 2017 Aug; 106(8):2136-2143. PubMed ID: 28389265
[TBL] [Abstract][Full Text] [Related]
15. Andexanet: Effectively Reversing Anticoagulation.
Lippi G; Sanchis-Gomar F; Favaloro EJ
Trends Pharmacol Sci; 2016 Jun; 37(6):413-414. PubMed ID: 27048885
[TBL] [Abstract][Full Text] [Related]
16. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
[TBL] [Abstract][Full Text] [Related]
17. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
Rogers KC; Finks SW
Am J Med; 2019 Jan; 132(1):38-41. PubMed ID: 30053385
[TBL] [Abstract][Full Text] [Related]
18. FXa-α2-Macroglobulin Complex Neutralizes Direct Oral Anticoagulants Targeting FXa In Vitro and In Vivo.
Jourdi G; Gouin-Thibault I; Siguret V; Gandrille S; Gaussem P; Le Bonniec B
Thromb Haemost; 2018 Sep; 118(9):1535-1544. PubMed ID: 30071567
[TBL] [Abstract][Full Text] [Related]
19. Reversal of anticoagulants: an overview of current developments.
Greinacher A; Thiele T; Selleng K
Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
[TBL] [Abstract][Full Text] [Related]
20. Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?
Papadaki S; Tselepis AD
Angiology; 2019 Nov; 70(10):896-907. PubMed ID: 31010298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
